rccep|拨云见日终有时|免疫治疗疗效预测标志物之RCCEP( 二 )


图3 基于OS的Landmark生存分析(3个月,左图)/
(5个月,右图)
【rccep|拨云见日终有时|免疫治疗疗效预测标志物之RCCEP】OS的3个月和5个月的Landmark生存分析显示,发生RCCEP患者相对于无RCCEP患者HR分别为0.57 (95% CI, 0.37~0.88;log-rank单侧P= 0.0101)和0.58 (95% CI, 0.35~0.97;log-rank单侧P=0.0351) 。因此,可以认为RCCEP具有类似于贝伐单抗引起的高血压和西妥昔单抗引起的皮疹对疗效的预测效应,将成为可以预测Cam疗效的临床标志物 。
多项研究结果均表明,RCCEP的发生与卡瑞利珠单抗单药治疗后的总生存期(OS)、客观缓解率(ORR)以及无进展生存期(PFS)有着密切关系,可将RCCEP作为一种临床标志物用来预测卡瑞利珠单抗单药的疗效 。
本文来源丨瑞e声
参考文献:
1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature,2017,541(7637): 321-330.
2. Bai J, Gao Z, Li X, et al.Regulation of PD-1/PD-L1 pathway and resistance to PD-1 /PD-L1 blockade[J].Oncotarget, 2017, 8(66):110693-110707.
3. Alsaab HO, Sau S, Alzhrani R, et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy:Mechanism, combinations and clinical outcome[J].Front Pharmacol, 2017(8):561.
4. 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 中国临床肿瘤学会免疫治疗专家委员会.卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识[J].2020,9,25(09).
5. Chen X, Ma L, Wang X, et al.Reactive capillary hemangiomas: a novel dermatofogie toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med,2019,16(1):173-181.
6. Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020,21(6):832-842.
7. Zhou C, Chen G, Huang Y, et al. A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced / metastatic non-squamous non-small cell lung cancer[J]. J Thorac Oncol,2019,14(10 Suppl):215-216.
8. 王锋, 秦叔逵, 方维佳, 等. 抗PD-1单抗SHR-1210治疗原发性肝癌引发皮肤毛细血管增生症的临床病理报告[J].临床肿瘤学杂志, 2017, 22(12):1066-1072.
9. Wang F, Qin SK, Sun XC, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab:data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020,13:47.

推荐阅读